Search

everythinglearnresearchcommunity

for

Search:↓

Higher levels of the protein Pannexin-1 may play a role in hair loss in women with PCOS.

ADT-G may be a useful indicator of increased androgen levels in women with acne and can be lowered with certain birth control pills.

A potential link exists between unexplained hormone deficiency, hair loss, and testicular tumors, suggesting thorough screening is needed.

Hair loss in males and females is influenced by immune cell interactions, with potential treatments identified.

Androgen replacement therapy can improve libido and mood in women with severe androgen deficiency, but more research is needed on its long-term safety.

A rare ovarian tumor caused high testosterone and excess hair in a woman, which was resolved after tumor removal.

Women with PCOS have higher androgen levels that decrease with age but are still higher than in women without PCOS.

Surgery removed an ovarian tumor, improving her symptoms and normalizing testosterone levels.

Immune cells and plasma proteins are linked to hair loss, suggesting new treatment options.

Hormone imbalances from the pituitary, thyroid, and adrenal glands can cause infertility, but treating these disorders can improve fertility.

Targeted nanomodulators can rejuvenate cells and promote hair growth in androgenetic alopecia.

Higher GPER-1 levels are linked to more severe and shorter-duration androgenetic alopecia, suggesting GPER-1 as a potential treatment target.

Early onset hair loss linked to genetics and androgen levels.

PCOS, aging, and fertility are linked by hormonal and metabolic issues, with lifestyle changes and treatments offering potential help.

Androgenic alopecia can be treated with minoxidil, finasteride, and hormonal therapy.

Higher testosterone and dehydroepiandrosterone sulphate levels may help diagnose meibomian gland dysfunction.

Women with PCOS have higher 5alpha-reductase activity, affecting steroid levels.

Hormones like estrogen, testosterone, progesterone, and prolactin play complex roles in female sexual function, with testosterone potentially improving sexual desire, arousal, and satisfaction. However, more research is needed to establish safe and effective hormone treatments for female sexual dysfunction.

The document explains how hair loss in men and women, known as Androgenetic alopecia, is categorized using the Hamilton-Norwood system for men and the Ludwig grade system for women.

AGA progression involves increased lipid synthesis, electron transport, and hair follicle miniaturization.

AKR1C enzymes in scalp glands decrease with age, possibly affecting hair loss.

Male hair loss is caused by inactive hair follicle stem cells.

Hirsutism and alopecia during menopause can be diagnosed and treated with specific hormonal and topical therapies.

Longer CAG and GGN repeats increase alopecia risk, but no significant link to post-finasteride syndrome found.

A substance called prostaglandin D2 is linked to stopping hair growth in men with common baldness.

People with early onset baldness (AGA) have higher blood sugar levels and lower sex hormone-binding globulin (SHBG) levels, suggesting SHBG could predict high blood sugar in these individuals.

AR gene not major factor in female hair loss; different from male hair loss.

Personalized hair loss treatments are needed for transgender individuals, but more research is required.

A man developed hair loss from testosterone treatment but improved with additional medication.